Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Gains from Investment Securities (2022 - 2025)

Core Laboratories (CLB) has 4 years of Gains from Investment Securities data on record, last reported at -$917000.0 in Q1 2025.

  • For Q1 2025, Gains from Investment Securities changed N/A year-over-year to -$917000.0; the TTM value through Mar 2025 reached -$361000.0, changed N/A, while the annual FY2024 figure was $900907.0, N/A changed from the prior year.
  • Gains from Investment Securities reached -$917000.0 in Q1 2025 per CLB's latest filing, down from $900907.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $900907.0 in Q4 2024 and bottomed at -$917000.0 in Q1 2025.
  • Average Gains from Investment Securities over 4 years is $107981.4, with a median of $436000.0 recorded in 2022.
  • The widest YoY moves for Gains from Investment Securities: up 223.26% in 2023, down 223.26% in 2023.
  • A 4-year view of Gains from Investment Securities shows it stood at $436000.0 in 2022, then soared by 45.87% to $636000.0 in 2023, then skyrocketed by 41.65% to $900907.0 in 2024, then crashed by 201.79% to -$917000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$917000.0 in Q1 2025, $900907.0 in Q4 2024, and $636000.0 in Q3 2023.